The Valley Desk

NCT01309789 · Interventional trial

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Overall registry status Completed

Phase 1

Conditions Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell, Lymphoma, T-cell

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov